BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 1826095)

  • 1. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.
    Gianese F; Nurmohamed MT; Imbimbo BP; Büller HR; Berckmans RJ; Ten Cate JW
    Br J Clin Pharmacol; 1993 Mar; 35(3):335-9. PubMed ID: 8471416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective assessment of heparin requirements for hemodialysis in humans.
    Ireland H; Lane DA; Curtis JR
    J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
    Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J
    Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term hemodialysis and changes in variables of coagulation and fibrinolysis].
    Uchida Y
    Fukuoka Igaku Zasshi; 1991 Nov; 82(11):576-85. PubMed ID: 1774013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.
    Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR
    Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
    Koga S
    Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of predictive state of disseminated intravascular coagulation].
    Yamamoto K; Saito H
    Nihon Rinsho; 1993 Jan; 51(1):74-8. PubMed ID: 8433531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
    Walenga JM; Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory application of radioimmunoassay in the quantitation of molecular markers of hemostatic activation.
    Walenga JM; Fareed J; Hoppensteadt D
    Semin Thromb Hemost; 1984 Oct; 10(4):294-305. PubMed ID: 6240117
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical tests on the diagnosis of thrombosis].
    Yamanaka M
    Nihon Rinsho; 1986 May; 44(5):1076-80. PubMed ID: 2943914
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.